See more : Medite Cancer Diagnostics, Inc. (MDIT) Income Statement Analysis – Financial Results
Complete financial analysis of DURECT Corporation (DRRX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of DURECT Corporation, a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
You may be interested
- Taiji Computer Corporation Limited (002368.SZ) Income Statement Analysis – Financial Results
- AEON Financial Service Co., Ltd. (8570.T) Income Statement Analysis – Financial Results
- Premier Limited (PREMIER.NS) Income Statement Analysis – Financial Results
- Tactical Resources Corp. (USREF) Income Statement Analysis – Financial Results
- CSL Finance Limited (CSLFINANCE.BO) Income Statement Analysis – Financial Results
DURECT Corporation (DRRX)
About DURECT Corporation
DURECT Corporation, a biopharmaceutical company, researches and develops medicines based on its epigenetic regulator and pharmaceutical programs. The company offers ALZET product line that consists of osmotic pumps and accessories used for research in mice, rats, and other laboratory animals. It also develops larsucosterol (DUR-928), an endogenous, orally bioavailable small molecule that is in Phase IIb clinical trial to play a regulatory role in lipid metabolism, stress and inflammatory responses, and cell death and survival to treat alcohol-associated hepatitis, as well as completed Phase Ib clinical trial to treat patients with nonalcoholic steatohepatitis. In addition, the company offers POSIMIR, a post-surgical pain product to deliver bupivacaine up to days of in adults; and Methydur to treat attention deficit hyperactivity disorder. It markets and sells its ALZET lines through direct sales force in the United States, as well as through a network of distributors in Japan, Europe, and internationally. The company has strategic collaboration and other agreements with Virginia Commonwealth University Intellectual Property Foundation; Indivior UK Ltd.; and Santen Pharmaceutical Co., Ltd. DURECT Corporation was incorporated in 1998 and is headquartered in Cupertino, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 8.55M | 19.28M | 13.98M | 30.11M | 29.56M | 18.56M | 49.17M | 14.03M | 19.12M | 19.40M | 15.33M | 53.07M | 33.49M | 31.59M | 24.29M | 25.96M | 30.68M | 21.89M | 28.57M | 13.85M | 11.84M | 7.19M | 6.52M | 3.16M | 86.00K |
| Cost of Revenue | 1.72M | 1.59M | 1.96M | 1.41M | 4.14M | 4.26M | 6.63M | 5.29M | 3.91M | 5.69M | 4.84M | 4.65M | 4.71M | 4.28M | 5.34M | 3.37M | 3.23M | 3.25M | 2.82M | 2.73M | 2.43M | 3.09M | 3.40M | 1.29M | -272.00K |
| Gross Profit | 6.83M | 17.70M | 12.02M | 28.71M | 25.42M | 14.30M | 42.54M | 8.74M | 15.22M | 13.72M | 10.49M | 48.42M | 28.77M | 27.32M | 18.95M | 22.59M | 27.45M | 18.65M | 25.76M | 11.12M | 9.41M | 4.10M | 3.13M | 1.86M | 358.00K |
| Gross Profit Ratio | 79.91% | 91.76% | 86.01% | 95.33% | 85.99% | 77.04% | 86.51% | 62.28% | 79.58% | 70.69% | 68.44% | 91.23% | 85.93% | 86.47% | 78.01% | 87.04% | 89.49% | 85.16% | 90.15% | 80.30% | 79.49% | 57.05% | 47.92% | 59.08% | 416.28% |
| Research & Development | 29.35M | 36.86M | 31.85M | 27.71M | 30.21M | 25.50M | 31.61M | 29.27M | 24.32M | 22.43M | 18.95M | 20.27M | 34.05M | 36.21M | 34.91M | 39.41M | 38.34M | 37.24M | 28.90M | 24.23M | 20.95M | 29.55M | 24.57M | 13.34M | 6.36M |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 12.42M | 13.17M | 11.83M | 11.57M | 12.28M | 12.71M | 12.10M | 13.57M | 14.94M | 15.02M | 15.46M | 13.62M | 12.42M | 11.27M | 9.95M | 8.40M | 12.17M | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 116.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 14.36M | 15.92M | 14.45M | 13.61M | 14.36M | 12.42M | 13.17M | 11.83M | 11.57M | 12.28M | 12.71M | 12.10M | 13.57M | 14.94M | 15.14M | 15.46M | 13.62M | 12.42M | 11.27M | 9.95M | 8.40M | 12.17M | 12.08M | 9.85M | 3.04M |
| Other Expenses | 0.00 | 23.66M | 25.52M | 3.77M | 12.08M | 17.29M | 8.03M | 27.39M | 16.49M | 14.17M | 15.36M | 0.00 | 11.69M | 16.12M | 22.45M | 48.00K | 31.00K | 424.00K | 1.21M | 1.25M | 1.34M | 1.34M | 1.84M | 1.50M | 311.00K |
| Operating Expenses | 43.72M | 52.78M | 46.30M | 41.32M | 44.57M | 37.92M | 44.77M | 41.10M | 35.88M | 34.71M | 31.65M | 32.36M | 47.63M | 51.15M | 50.05M | 68.40M | 51.99M | 50.08M | 41.38M | 35.43M | 30.69M | 43.07M | 38.50M | 24.69M | 9.72M |
| Cost & Expenses | 45.43M | 54.37M | 48.25M | 42.73M | 48.72M | 42.18M | 51.41M | 46.39M | 39.79M | 40.40M | 36.49M | 37.01M | 52.34M | 55.43M | 55.39M | 71.77M | 55.22M | 53.33M | 44.20M | 38.16M | 33.11M | 46.15M | 41.90M | 25.98M | 9.45M |
| Interest Income | 2.13M | 2.15M | 156.00K | 517.00K | 1.07M | 870.00K | 967.00K | 143.00K | 237.00K | 39.00K | 0.00 | 151.00K | 134.00K | 943.00K | 420.00K | 1.55M | 0.00 | 3.83M | 2.27M | 0.00 | 1.04M | 0.00 | 0.00 | 3.10M | 0.00 |
| Interest Expense | 2.79M | 2.40M | 2.15M | 2.24M | 2.50M | 2.57M | 2.43M | 2.29M | 2.24M | 1.15M | 290.00K | 7.00K | 46.00K | 6.00K | 36.00K | 789.00K | 2.63M | 3.44M | 4.36M | 0.00 | 2.46M | 0.00 | 0.00 | 131.00K | 0.00 |
| Depreciation & Amortization | 148.00K | 150.00K | 132.00K | 297.00K | 291.00K | 254.00K | 437.00K | 416.00K | 425.00K | 601.00K | 558.00K | 964.00K | 1.18M | 2.25M | 2.51M | 48.00K | 2.32M | 2.46M | 3.17M | 4.64M | 4.75M | 4.32M | 3.30M | 1.50M | 311.00K |
| EBITDA | -24.68M | -32.78M | -33.99M | -11.80M | -18.58M | -22.50M | -833.00K | -31.81M | -20.00M | -20.36M | -20.60M | 17.16M | -17.59M | -20.64M | -27.75M | -45.76M | -22.22M | -28.97M | -12.46M | -18.43M | -16.53M | -34.65M | -32.07M | -21.32M | -9.05M |
| EBITDA Ratio | -288.77% | -170.79% | -244.09% | -40.18% | -61.15% | -122.54% | -2.58% | -229.74% | -106.81% | -108.03% | -138.08% | 32.36% | -56.30% | -75.45% | -129.75% | -176.30% | -70.11% | -121.89% | -42.20% | -141.98% | -139.70% | -482.25% | -276.58% | -675.85% | -10,520.93% |
| Operating Income | -36.88M | -35.08M | -34.27M | -12.62M | -19.15M | -23.62M | -2.24M | -32.36M | -20.66M | -21.00M | -21.16M | 16.06M | -18.85M | -23.84M | -31.10M | -45.81M | -24.54M | -31.44M | -15.63M | -24.31M | -21.28M | -38.97M | -49.40M | -22.82M | -9.36M |
| Operating Income Ratio | -431.49% | -181.93% | -245.21% | -41.89% | -64.78% | -127.23% | -4.55% | -230.76% | -108.05% | -108.23% | -138.08% | 30.25% | -56.30% | -75.45% | -128.02% | -176.48% | -80.00% | -143.58% | -54.70% | -175.48% | -179.80% | -542.37% | -757.23% | -723.39% | -10,882.56% |
| Total Other Income/Expenses | 9.26M | -251.00K | -1.99M | -1.72M | -1.43M | -1.70M | -1.46M | -2.15M | -2.00M | -1.11M | -290.00K | 144.00K | 88.00K | 937.00K | 811.00K | 758.00K | 202.00K | -1.89M | -2.50M | -3.31M | -1.42M | 1.80M | 4.47M | 0.00 | 0.00 |
| Income Before Tax | -27.62M | -35.33M | -36.27M | -14.34M | -20.58M | -25.32M | -3.70M | -34.51M | -22.66M | -22.11M | -21.45M | 16.20M | -18.77M | -22.90M | -30.29M | -43.91M | -24.34M | -33.33M | -18.12M | -27.62M | -22.70M | -37.17M | -44.93M | 0.00 | 0.00 |
| Income Before Tax Ratio | -323.16% | -183.23% | -259.46% | -47.61% | -69.60% | -136.40% | -7.51% | -246.05% | -118.51% | -113.96% | -139.97% | 30.53% | -56.04% | -72.48% | -124.68% | -169.15% | -79.34% | -152.22% | -63.43% | -199.37% | -191.79% | -517.37% | -688.66% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | 251.00K | 1.86M | -11.81M | 2.21M | 870.00K | 530.00K | -273.00K | -188.00K | -562.00K | -558.00K | 151.00K | -1.18M | -2.25M | -2.89M | -12.69M | -202.00K | 1.89M | 4.00K | 18.00K | 0.00 | 0.00 | 9.56M | -2.97M | -651.00K |
| Net Income | -27.62M | -35.58M | -38.13M | -2.52M | -22.79M | -25.32M | -3.70M | -34.51M | -22.66M | -22.11M | -21.45M | 16.20M | -18.77M | -22.90M | -30.72M | -45.05M | -24.34M | -33.33M | -18.13M | -27.64M | -22.70M | -37.17M | -44.93M | -19.85M | -8.71M |
| Net Income Ratio | -323.16% | -184.54% | -272.77% | -8.38% | -77.08% | -136.40% | -7.51% | -246.05% | -118.51% | -113.96% | -139.97% | 30.53% | -56.04% | -72.48% | -126.44% | -173.56% | -79.34% | -152.22% | -63.45% | -199.50% | -191.79% | -517.37% | -688.66% | -629.19% | -10,125.58% |
| EPS | -1.22 | -1.56 | -1.69 | -0.13 | -1.28 | -1.60 | -0.25 | -2.60 | -1.91 | -2.00 | -2.10 | 1.80 | -2.15 | -2.64 | -3.68 | -5.75 | -3.45 | -5.05 | -3.37 | -5.37 | -4.49 | -7.69 | -9.68 | -11.60 | -3.66 |
| EPS Diluted | -1.20 | -1.56 | -1.69 | -0.13 | -1.28 | -1.58 | -0.25 | -2.59 | -1.91 | -1.98 | -2.08 | 1.80 | -2.15 | -2.64 | -3.68 | -5.75 | -3.45 | -5.05 | -3.37 | -5.37 | -4.49 | -7.69 | -9.68 | -6.01 | -3.66 |
| Weighted Avg Shares Out | 26.26M | 22.78M | 22.50M | 19.95M | 17.80M | 15.84M | 14.53M | 13.27M | 11.85M | 11.06M | 10.22M | 8.84M | 8.74M | 8.69M | 8.34M | 7.83M | 7.05M | 6.60M | 5.37M | 5.15M | 5.05M | 4.83M | 4.64M | 1.71M | 2.38M |
| Weighted Avg Shares Out (Dil) | 26.52M | 22.78M | 22.50M | 19.95M | 17.80M | 15.98M | 14.53M | 13.32M | 11.85M | 11.17M | 10.31M | 8.86M | 8.74M | 8.69M | 8.34M | 7.83M | 7.05M | 6.60M | 5.37M | 5.15M | 5.05M | 4.83M | 4.64M | 3.31M | 2.38M |
DURECT Corporation to Host KOL Event on Alcohol-Associated Hepatitis
CUPERTINO, Calif., April 27, 2023 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) today announced it will host a Key Opinion Leader (“KOL”) event on Alcohol-Associated Hepatitis on May 16th in New York City. Topics of discussion will include the etiology and...
DURECT Corporation to Participate in Fireside Chat at the H.C. Wainwright BioConnect Investor Conference
CUPERTINO, Calif. , April 25, 2023 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced that Dr. James Brown, President and CEO, will participate in a fireside chat hosted by Ed Arce, Managing Director, Senior Biotechnology Research Analyst, H.C Wainwright &...
Durect (DRRX) Reports Q4 Loss, Tops Revenue Estimates
Durect (DRRX) delivered earnings and revenue surprises of 13.21% and 2.79%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
DURECT Corporation to Announce Fourth Quarter and Full Year 2022 Financial Results and Provide Business Update on March 7
CUPERTINO, Calif. , Feb. 28, 2023 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced that it will report its fourth quarter and full year 2022 financial results and host a conference call after the market close on Tuesday, March 7,...
Durect (DRRX) Soars 11.8%: Is Further Upside Left in the Stock?
Durect (DRRX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
DURECT Corporation (DRRX) Q3 2022 Earnings Call Transcript
DURECT Corporation (NASDAQ:DRRX ) Q3 2022 Earnings Conference Call November 2, 2022 4:30 PM ET Company Participants Tim Papp - Chief Financial Officer Jim Brown - Chief Executive Officer Norman Sussman - Chief Medical Officer Keith Louie - Business Development...
DURECT Corporation to Announce Third Quarter 2022 Financial Results and Provide Business Update on November 2
CUPERTINO, Calif. , Oct. 26, 2022 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced that it will report its third quarter 2022 financial results and host a conference call after the market close on Wednesday, November 2, 2022.
DURECT Corporation's (DRRX) CEO Jim Brown on Q2 2022 Results - Earnings Call Transcript
DURECT Corporation (NASDAQ:DRRX ) Q2 2022 Earnings Conference Call August 4, 2022 4:30 PM ET Company Participants Tim Papp - Chief Financial Officer Jim Brown - Chief Executive Officer Norman Sussman - Chief Medical Officer Conference Call Participants Rick Miller...
Durect (DRRX) Reports Q2 Loss, Lags Revenue Estimates
Durect (DRRX) delivered earnings and revenue surprises of -25% and 59.01%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
DURECT Corporation to Present at the H.C. Wainwright Global Investment Conference
CUPERTINO, Calif. , May 18, 2022 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced that Dr. James E.
Source: https://incomestatements.info
Category: Stock Reports